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The ability of tissue dwelling helminth parasites to induce chronic long term 
infections, is enabled by the establishment of T helper 2/ regulatory T cell (Th2/Treg) 
immune responses within their mammalian hosts. Such responses prevent the expulsion 
of the parasites, whilst simultaneously avoiding excessive inflammation/fibrosis arising 
within the host, as a consequence of tissue damage induced by helminth migration. 
Importantly, helminths excrete and secrete a series of molecules (collectively known as 
ES products), which not only play major roles in parasite biology, but also exert direct 
immune modulatory functions, promoting the establishment of Th2/Treg immunity. The 
trematode, Fasciola hepatica, is an excellent model of helminth-mediated immune 
modulation, because it induces a very rapid switch towards Th2 responses in its 
mammalian hosts and inhibits Th1 immunity.  Fractionation of the ES products of F. 
hepatica has identified three major immune modulatory components: the protease 
cathepsin L1, the antioxidant peroxiredoxin, and a previously uncharacterised peptide, 
FhHDM-1.  
Structural analysis of FhHDM-1 revealed a close resemblance to the 
cathelicidin, LL-37, a well characterised mammalian immune-modulating peptide. 
Therefore, a putative immune modulatory role for FhHDM-1 was explored in this 
project. Immunofluorescent confocal microscopy demonstrated that FhHDM-1 
interacted with macrophage lipid rafts, prior to being actively internalised by 
cholesterol- and cytoskeletal network-dependent endocytosis, with progressive 
compartmentalisation of the peptide into early endosomes and endolysosomal vesicles. 
Flow cytometry studies indicated that, once internalised, FhHDM-1 enhanced the rate of 
endocytosis of dextran by macrophages. Despite this, FhHDM-1 was found to impair 
the acidification of macrophage endolysosomes and as a consequence, the efficient 
processing and subsequent presentation of ovalbumin to T cells was prevented, as 
assessed by decreased detection of digested fluorescent ovalbumin and reduced IL-2 
secretion by transgenic CD4+ T cells. Additionally, FhHDM-1 impaired NLRP3 
inflammasome activation by lysosomal disruptive agents in macrophages. This was 
found to be a consequence of reduced cathepsin B activity (due to FhHDM-1 induced 
suboptimal lysosomal acidification), which was incapable of stimulating inflammasome 
complex formation, thus avoiding IL-1β and caspase-1 cleavage.  
xvii 
 
These findings suggest that by targeting endolysosomal activity, FhHDM-1 
limits macrophage function. Therefore, the current study is the first to demonstrate that 
FhHDM-1 possesses immune modulatory properties, which are directed by a 
mechanism not previously described for a helminth-secreted cathelicidin-like peptide. 
  
